News Home

How Will the Market React to Geovax Labs Inc (GOVX) Stock Getting a Bearish Rating

Thursday, August 19, 2021 03:05 PM | InvestorsObserver Analysts
How Will the Market React to Geovax Labs Inc (GOVX) Stock Getting a Bearish Rating

The market has been down on Geovax Labs Inc (GOVX) stock recently. GOVX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Geovax Labs Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GOVX!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GOVX Stock Today?

Geovax Labs Inc (GOVX) stock has gained 7.57% while the S&P 500 is lower by -0.18% as of 2:38 PM on Thursday, Aug 19. GOVX is higher by $0.30 from the previous closing price of $4.03 on volume of 10,017,668 shares. Over the past year the S&P 500 is higher by 29.58% while GOVX is lower by -61.59%. GOVX lost -$1.58 per share in the over the last 12 months.

More About Geovax Labs Inc

Geovax Labs Inc is US-based clinical-stage biotechnology company. It is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a novel patented Modified Vaccinia Ankara-Virus Like Particle (GV-MVA-VLP) vector vaccine platform. The development programs of the company focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses, and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The product pipeline includes HIV-Clade B Preventive Vaccine, HIV-Clade B Immunotherapy, Hemorrhagic Fever Vaccines, Zika Vaccine, Malaria vaccine, and Cancer Immunotherapy. Click Here to get the full Stock Report for Geovax Labs Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App